Crinetics prices $350M common stock offering at $45.95/share to fund PALSONIFY launch

Crinetics Pharmaceuticals, Inc.

Pricing: 7,620,000 shares at $45.95/share; gross proceeds ~$350M.
Underwriters granted 30-day option to buy up to 1,143,000 additional shares.
Net proceeds expected ~$330.2M, or ~$379.8M if option exercised.
Proceeds to fund commercial launch of PALSONIFY, R&D, and general corporate purposes.
Offering expected to close January 8, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.